The F.D.A. has rejected ivonescimab, a lung cancer drug from China, according to a report by The New York Times. The report was published on November 15, 2026, and was written by reporter Rebecca Robbins.
The New York Times reported that the treatment has become a symbol of China’s rise in drug development. The newspaper's summary of the report describes the drug in those terms and identifies it by name.
The summary does not state the reasons the F.D.A. gave for rejecting the drug or when the decision was made. It also does not include any response from the agency or from other parties involved in the drug's review.
The New York Times headline describes the drug as closely watched, and the summary links the treatment to broader attention on China's role in pharmaceutical development, as the newspaper reported.
This account is limited to the headline, summary, author name and publication date supplied with the report. No additional reporting was reviewed for this story, and the details above have not been independently confirmed.
Readers seeking the full account, including any statements from the agency, should consult the complete New York Times report on its website.
Sources: The New York Times: F.D.A. Rejects Closely Watched Lung Cancer Drug From China.